nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—Naftifine—Tamoxifen—pancreatic cancer	0.47	1	CrCrCtD
Duloxetine—CYP1A2—Dacarbazine—pancreatic cancer	0.0363	0.22	CbGbCtD
Duloxetine—CYP1A2—Tamoxifen—pancreatic cancer	0.0289	0.175	CbGbCtD
Duloxetine—CYP1A2—Erlotinib—pancreatic cancer	0.0246	0.149	CbGbCtD
Duloxetine—CYP2D6—Tamoxifen—pancreatic cancer	0.0238	0.144	CbGbCtD
Duloxetine—CYP1A2—Fluorouracil—pancreatic cancer	0.0213	0.129	CbGbCtD
Duloxetine—CYP2D6—Erlotinib—pancreatic cancer	0.0202	0.123	CbGbCtD
Duloxetine—CYP2D6—Doxorubicin—pancreatic cancer	0.00998	0.0605	CbGbCtD
Duloxetine—Dysuria—Doxorubicin—pancreatic cancer	0.000122	0.000493	CcSEcCtD
Duloxetine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000122	0.000491	CcSEcCtD
Duloxetine—Dry mouth—Docetaxel—pancreatic cancer	0.000121	0.00049	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000121	0.00049	CcSEcCtD
Duloxetine—Pollakiuria—Doxorubicin—pancreatic cancer	0.000121	0.000487	CcSEcCtD
Duloxetine—Asthenia—Gemcitabine—pancreatic cancer	0.00012	0.000486	CcSEcCtD
Duloxetine—Confusional state—Docetaxel—pancreatic cancer	0.00012	0.000485	CcSEcCtD
Duloxetine—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000119	0.000481	CcSEcCtD
Duloxetine—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000119	0.000481	CcSEcCtD
Duloxetine—Oedema—Docetaxel—pancreatic cancer	0.000119	0.000481	CcSEcCtD
Duloxetine—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000119	0.000481	CcSEcCtD
Duloxetine—Weight increased—Doxorubicin—pancreatic cancer	0.000119	0.00048	CcSEcCtD
Duloxetine—Epistaxis—Epirubicin—pancreatic cancer	0.000119	0.000479	CcSEcCtD
Duloxetine—Pruritus—Gemcitabine—pancreatic cancer	0.000119	0.000479	CcSEcCtD
Duloxetine—Infection—Docetaxel—pancreatic cancer	0.000118	0.000477	CcSEcCtD
Duloxetine—Weight decreased—Doxorubicin—pancreatic cancer	0.000118	0.000477	CcSEcCtD
Duloxetine—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000118	0.000476	CcSEcCtD
Duloxetine—Diarrhoea—Irinotecan—pancreatic cancer	0.000118	0.000476	CcSEcCtD
Duloxetine—Shock—Docetaxel—pancreatic cancer	0.000117	0.000473	CcSEcCtD
Duloxetine—Nervous system disorder—Docetaxel—pancreatic cancer	0.000117	0.000471	CcSEcCtD
Duloxetine—Pruritus—Fluorouracil—pancreatic cancer	0.000117	0.000471	CcSEcCtD
Duloxetine—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000117	0.000471	CcSEcCtD
Duloxetine—Infestation NOS—Doxorubicin—pancreatic cancer	0.000117	0.00047	CcSEcCtD
Duloxetine—Infestation—Doxorubicin—pancreatic cancer	0.000117	0.00047	CcSEcCtD
Duloxetine—Tachycardia—Docetaxel—pancreatic cancer	0.000116	0.000469	CcSEcCtD
Duloxetine—Skin disorder—Docetaxel—pancreatic cancer	0.000116	0.000467	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000116	0.000466	CcSEcCtD
Duloxetine—Diarrhoea—Gemcitabine—pancreatic cancer	0.000115	0.000463	CcSEcCtD
Duloxetine—Renal failure—Doxorubicin—pancreatic cancer	0.000115	0.000462	CcSEcCtD
Duloxetine—Dizziness—Irinotecan—pancreatic cancer	0.000114	0.00046	CcSEcCtD
Duloxetine—Haemoglobin—Epirubicin—pancreatic cancer	0.000114	0.000459	CcSEcCtD
Duloxetine—Stomatitis—Doxorubicin—pancreatic cancer	0.000114	0.000458	CcSEcCtD
Duloxetine—Jaundice—Doxorubicin—pancreatic cancer	0.000114	0.000458	CcSEcCtD
Duloxetine—Anorexia—Docetaxel—pancreatic cancer	0.000113	0.000458	CcSEcCtD
Duloxetine—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000113	0.000457	CcSEcCtD
Duloxetine—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000113	0.000457	CcSEcCtD
Duloxetine—Hepatitis—Epirubicin—pancreatic cancer	0.000113	0.000456	CcSEcCtD
Duloxetine—Haemorrhage—Epirubicin—pancreatic cancer	0.000113	0.000456	CcSEcCtD
Duloxetine—Diarrhoea—Fluorouracil—pancreatic cancer	0.000113	0.000456	CcSEcCtD
Duloxetine—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000112	0.000454	CcSEcCtD
Duloxetine—Pharyngitis—Epirubicin—pancreatic cancer	0.000112	0.000453	CcSEcCtD
Duloxetine—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000112	0.000451	CcSEcCtD
Duloxetine—Oedema peripheral—Epirubicin—pancreatic cancer	0.000111	0.000449	CcSEcCtD
Duloxetine—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000111	0.000448	CcSEcCtD
Duloxetine—Urethral disorder—Epirubicin—pancreatic cancer	0.000111	0.000447	CcSEcCtD
Duloxetine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.00011	0.000445	CcSEcCtD
Duloxetine—Epistaxis—Doxorubicin—pancreatic cancer	0.00011	0.000444	CcSEcCtD
Duloxetine—Vomiting—Irinotecan—pancreatic cancer	0.00011	0.000442	CcSEcCtD
Duloxetine—Dizziness—Fluorouracil—pancreatic cancer	0.000109	0.00044	CcSEcCtD
Duloxetine—Visual impairment—Epirubicin—pancreatic cancer	0.000109	0.00044	CcSEcCtD
Duloxetine—Rash—Irinotecan—pancreatic cancer	0.000109	0.000438	CcSEcCtD
Duloxetine—Dermatitis—Irinotecan—pancreatic cancer	0.000109	0.000438	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000108	0.000438	CcSEcCtD
Duloxetine—Headache—Irinotecan—pancreatic cancer	0.000108	0.000435	CcSEcCtD
Duloxetine—Insomnia—Docetaxel—pancreatic cancer	0.000108	0.000435	CcSEcCtD
Duloxetine—Paraesthesia—Docetaxel—pancreatic cancer	0.000107	0.000432	CcSEcCtD
Duloxetine—Erythema multiforme—Epirubicin—pancreatic cancer	0.000107	0.000431	CcSEcCtD
Duloxetine—Vomiting—Gemcitabine—pancreatic cancer	0.000107	0.000431	CcSEcCtD
Duloxetine—Somnolence—Docetaxel—pancreatic cancer	0.000106	0.000427	CcSEcCtD
Duloxetine—Rash—Gemcitabine—pancreatic cancer	0.000106	0.000427	CcSEcCtD
Duloxetine—Dermatitis—Gemcitabine—pancreatic cancer	0.000106	0.000427	CcSEcCtD
Duloxetine—Eye disorder—Epirubicin—pancreatic cancer	0.000106	0.000426	CcSEcCtD
Duloxetine—Tinnitus—Epirubicin—pancreatic cancer	0.000105	0.000425	CcSEcCtD
Duloxetine—Haemoglobin—Doxorubicin—pancreatic cancer	0.000105	0.000424	CcSEcCtD
Duloxetine—Headache—Gemcitabine—pancreatic cancer	0.000105	0.000424	CcSEcCtD
Duloxetine—Cardiac disorder—Epirubicin—pancreatic cancer	0.000105	0.000423	CcSEcCtD
Duloxetine—Flushing—Epirubicin—pancreatic cancer	0.000105	0.000423	CcSEcCtD
Duloxetine—Vomiting—Fluorouracil—pancreatic cancer	0.000105	0.000423	CcSEcCtD
Duloxetine—Dyspepsia—Docetaxel—pancreatic cancer	0.000105	0.000423	CcSEcCtD
Duloxetine—Haemorrhage—Doxorubicin—pancreatic cancer	0.000105	0.000422	CcSEcCtD
Duloxetine—Hepatitis—Doxorubicin—pancreatic cancer	0.000105	0.000422	CcSEcCtD
Duloxetine—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000104	0.00042	CcSEcCtD
Duloxetine—Rash—Fluorouracil—pancreatic cancer	0.000104	0.00042	CcSEcCtD
Duloxetine—Dermatitis—Fluorouracil—pancreatic cancer	0.000104	0.000419	CcSEcCtD
Duloxetine—Pharyngitis—Doxorubicin—pancreatic cancer	0.000104	0.000419	CcSEcCtD
Duloxetine—Decreased appetite—Docetaxel—pancreatic cancer	0.000104	0.000418	CcSEcCtD
Duloxetine—Headache—Fluorouracil—pancreatic cancer	0.000103	0.000417	CcSEcCtD
Duloxetine—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000103	0.000417	CcSEcCtD
Duloxetine—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000103	0.000416	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000103	0.000415	CcSEcCtD
Duloxetine—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000103	0.000415	CcSEcCtD
Duloxetine—Fatigue—Docetaxel—pancreatic cancer	0.000103	0.000414	CcSEcCtD
Duloxetine—Angiopathy—Epirubicin—pancreatic cancer	0.000103	0.000414	CcSEcCtD
Duloxetine—Urethral disorder—Doxorubicin—pancreatic cancer	0.000103	0.000414	CcSEcCtD
Duloxetine—Nausea—Irinotecan—pancreatic cancer	0.000102	0.000413	CcSEcCtD
Duloxetine—Immune system disorder—Epirubicin—pancreatic cancer	0.000102	0.000412	CcSEcCtD
Duloxetine—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000102	0.000411	CcSEcCtD
Duloxetine—Constipation—Docetaxel—pancreatic cancer	0.000102	0.000411	CcSEcCtD
Duloxetine—Pain—Docetaxel—pancreatic cancer	0.000102	0.000411	CcSEcCtD
Duloxetine—Chills—Epirubicin—pancreatic cancer	0.000101	0.000409	CcSEcCtD
Duloxetine—Arrhythmia—Epirubicin—pancreatic cancer	0.000101	0.000408	CcSEcCtD
Duloxetine—Visual impairment—Doxorubicin—pancreatic cancer	0.000101	0.000407	CcSEcCtD
Duloxetine—Alopecia—Epirubicin—pancreatic cancer	9.99e-05	0.000403	CcSEcCtD
Duloxetine—Nausea—Gemcitabine—pancreatic cancer	9.97e-05	0.000402	CcSEcCtD
Duloxetine—Mental disorder—Epirubicin—pancreatic cancer	9.9e-05	0.0004	CcSEcCtD
Duloxetine—Erythema multiforme—Doxorubicin—pancreatic cancer	9.89e-05	0.000399	CcSEcCtD
Duloxetine—Erythema—Epirubicin—pancreatic cancer	9.84e-05	0.000397	CcSEcCtD
Duloxetine—Malnutrition—Epirubicin—pancreatic cancer	9.84e-05	0.000397	CcSEcCtD
Duloxetine—Feeling abnormal—Docetaxel—pancreatic cancer	9.81e-05	0.000396	CcSEcCtD
Duloxetine—Nausea—Fluorouracil—pancreatic cancer	9.8e-05	0.000395	CcSEcCtD
Duloxetine—Eye disorder—Doxorubicin—pancreatic cancer	9.77e-05	0.000394	CcSEcCtD
Duloxetine—Tinnitus—Doxorubicin—pancreatic cancer	9.75e-05	0.000394	CcSEcCtD
Duloxetine—Gastrointestinal pain—Docetaxel—pancreatic cancer	9.74e-05	0.000393	CcSEcCtD
Duloxetine—Flushing—Doxorubicin—pancreatic cancer	9.71e-05	0.000392	CcSEcCtD
Duloxetine—Cardiac disorder—Doxorubicin—pancreatic cancer	9.71e-05	0.000392	CcSEcCtD
Duloxetine—Flatulence—Epirubicin—pancreatic cancer	9.7e-05	0.000391	CcSEcCtD
Duloxetine—Tension—Epirubicin—pancreatic cancer	9.66e-05	0.00039	CcSEcCtD
Duloxetine—Dysgeusia—Epirubicin—pancreatic cancer	9.64e-05	0.000389	CcSEcCtD
Duloxetine—Nervousness—Epirubicin—pancreatic cancer	9.56e-05	0.000386	CcSEcCtD
Duloxetine—Back pain—Epirubicin—pancreatic cancer	9.52e-05	0.000384	CcSEcCtD
Duloxetine—Angiopathy—Doxorubicin—pancreatic cancer	9.49e-05	0.000383	CcSEcCtD
Duloxetine—Muscle spasms—Epirubicin—pancreatic cancer	9.46e-05	0.000382	CcSEcCtD
Duloxetine—Immune system disorder—Doxorubicin—pancreatic cancer	9.45e-05	0.000381	CcSEcCtD
Duloxetine—Mediastinal disorder—Doxorubicin—pancreatic cancer	9.43e-05	0.00038	CcSEcCtD
Duloxetine—Abdominal pain—Docetaxel—pancreatic cancer	9.41e-05	0.00038	CcSEcCtD
Duloxetine—Body temperature increased—Docetaxel—pancreatic cancer	9.41e-05	0.00038	CcSEcCtD
Duloxetine—Chills—Doxorubicin—pancreatic cancer	9.39e-05	0.000379	CcSEcCtD
Duloxetine—Arrhythmia—Doxorubicin—pancreatic cancer	9.34e-05	0.000377	CcSEcCtD
Duloxetine—Vision blurred—Epirubicin—pancreatic cancer	9.27e-05	0.000374	CcSEcCtD
Duloxetine—Alopecia—Doxorubicin—pancreatic cancer	9.24e-05	0.000373	CcSEcCtD
Duloxetine—Mental disorder—Doxorubicin—pancreatic cancer	9.16e-05	0.00037	CcSEcCtD
Duloxetine—Ill-defined disorder—Epirubicin—pancreatic cancer	9.13e-05	0.000368	CcSEcCtD
Duloxetine—Erythema—Doxorubicin—pancreatic cancer	9.11e-05	0.000367	CcSEcCtD
Duloxetine—Malnutrition—Doxorubicin—pancreatic cancer	9.11e-05	0.000367	CcSEcCtD
Duloxetine—Anaemia—Epirubicin—pancreatic cancer	9.1e-05	0.000367	CcSEcCtD
Duloxetine—Agitation—Epirubicin—pancreatic cancer	9.04e-05	0.000365	CcSEcCtD
Duloxetine—Flatulence—Doxorubicin—pancreatic cancer	8.97e-05	0.000362	CcSEcCtD
Duloxetine—Tension—Doxorubicin—pancreatic cancer	8.93e-05	0.000361	CcSEcCtD
Duloxetine—Dysgeusia—Doxorubicin—pancreatic cancer	8.92e-05	0.00036	CcSEcCtD
Duloxetine—Malaise—Epirubicin—pancreatic cancer	8.87e-05	0.000358	CcSEcCtD
Duloxetine—Nervousness—Doxorubicin—pancreatic cancer	8.84e-05	0.000357	CcSEcCtD
Duloxetine—Vertigo—Epirubicin—pancreatic cancer	8.84e-05	0.000357	CcSEcCtD
Duloxetine—Syncope—Epirubicin—pancreatic cancer	8.82e-05	0.000356	CcSEcCtD
Duloxetine—Leukopenia—Epirubicin—pancreatic cancer	8.81e-05	0.000355	CcSEcCtD
Duloxetine—Back pain—Doxorubicin—pancreatic cancer	8.81e-05	0.000355	CcSEcCtD
Duloxetine—Hypersensitivity—Docetaxel—pancreatic cancer	8.77e-05	0.000354	CcSEcCtD
Duloxetine—Muscle spasms—Doxorubicin—pancreatic cancer	8.75e-05	0.000353	CcSEcCtD
Duloxetine—Palpitations—Epirubicin—pancreatic cancer	8.7e-05	0.000351	CcSEcCtD
Duloxetine—Loss of consciousness—Epirubicin—pancreatic cancer	8.65e-05	0.000349	CcSEcCtD
Duloxetine—Cough—Epirubicin—pancreatic cancer	8.59e-05	0.000347	CcSEcCtD
Duloxetine—Vision blurred—Doxorubicin—pancreatic cancer	8.58e-05	0.000346	CcSEcCtD
Duloxetine—Asthenia—Docetaxel—pancreatic cancer	8.54e-05	0.000345	CcSEcCtD
Duloxetine—Convulsion—Epirubicin—pancreatic cancer	8.53e-05	0.000344	CcSEcCtD
Duloxetine—Hypertension—Epirubicin—pancreatic cancer	8.5e-05	0.000343	CcSEcCtD
Duloxetine—Ill-defined disorder—Doxorubicin—pancreatic cancer	8.45e-05	0.000341	CcSEcCtD
Duloxetine—Pruritus—Docetaxel—pancreatic cancer	8.42e-05	0.00034	CcSEcCtD
Duloxetine—Anaemia—Doxorubicin—pancreatic cancer	8.42e-05	0.00034	CcSEcCtD
Duloxetine—Chest pain—Epirubicin—pancreatic cancer	8.38e-05	0.000338	CcSEcCtD
Duloxetine—Arthralgia—Epirubicin—pancreatic cancer	8.38e-05	0.000338	CcSEcCtD
Duloxetine—Myalgia—Epirubicin—pancreatic cancer	8.38e-05	0.000338	CcSEcCtD
Duloxetine—Agitation—Doxorubicin—pancreatic cancer	8.37e-05	0.000338	CcSEcCtD
Duloxetine—Anxiety—Epirubicin—pancreatic cancer	8.35e-05	0.000337	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	8.32e-05	0.000336	CcSEcCtD
Duloxetine—Discomfort—Epirubicin—pancreatic cancer	8.28e-05	0.000334	CcSEcCtD
Duloxetine—Malaise—Doxorubicin—pancreatic cancer	8.21e-05	0.000331	CcSEcCtD
Duloxetine—Dry mouth—Epirubicin—pancreatic cancer	8.19e-05	0.000331	CcSEcCtD
Duloxetine—Vertigo—Doxorubicin—pancreatic cancer	8.18e-05	0.00033	CcSEcCtD
Duloxetine—Syncope—Doxorubicin—pancreatic cancer	8.17e-05	0.00033	CcSEcCtD
Duloxetine—Leukopenia—Doxorubicin—pancreatic cancer	8.15e-05	0.000329	CcSEcCtD
Duloxetine—Diarrhoea—Docetaxel—pancreatic cancer	8.15e-05	0.000329	CcSEcCtD
Duloxetine—Confusional state—Epirubicin—pancreatic cancer	8.1e-05	0.000327	CcSEcCtD
Duloxetine—Palpitations—Doxorubicin—pancreatic cancer	8.05e-05	0.000325	CcSEcCtD
Duloxetine—Anaphylactic shock—Epirubicin—pancreatic cancer	8.03e-05	0.000324	CcSEcCtD
Duloxetine—Oedema—Epirubicin—pancreatic cancer	8.03e-05	0.000324	CcSEcCtD
Duloxetine—Loss of consciousness—Doxorubicin—pancreatic cancer	8e-05	0.000323	CcSEcCtD
Duloxetine—Infection—Epirubicin—pancreatic cancer	7.98e-05	0.000322	CcSEcCtD
Duloxetine—Cough—Doxorubicin—pancreatic cancer	7.95e-05	0.000321	CcSEcCtD
Duloxetine—Shock—Epirubicin—pancreatic cancer	7.9e-05	0.000319	CcSEcCtD
Duloxetine—Convulsion—Doxorubicin—pancreatic cancer	7.89e-05	0.000318	CcSEcCtD
Duloxetine—Nervous system disorder—Epirubicin—pancreatic cancer	7.88e-05	0.000318	CcSEcCtD
Duloxetine—Dizziness—Docetaxel—pancreatic cancer	7.87e-05	0.000318	CcSEcCtD
Duloxetine—Thrombocytopenia—Epirubicin—pancreatic cancer	7.86e-05	0.000317	CcSEcCtD
Duloxetine—Hypertension—Doxorubicin—pancreatic cancer	7.86e-05	0.000317	CcSEcCtD
Duloxetine—Tachycardia—Epirubicin—pancreatic cancer	7.84e-05	0.000316	CcSEcCtD
Duloxetine—Skin disorder—Epirubicin—pancreatic cancer	7.8e-05	0.000315	CcSEcCtD
Duloxetine—Hyperhidrosis—Epirubicin—pancreatic cancer	7.76e-05	0.000313	CcSEcCtD
Duloxetine—Arthralgia—Doxorubicin—pancreatic cancer	7.75e-05	0.000313	CcSEcCtD
Duloxetine—Myalgia—Doxorubicin—pancreatic cancer	7.75e-05	0.000313	CcSEcCtD
Duloxetine—Chest pain—Doxorubicin—pancreatic cancer	7.75e-05	0.000313	CcSEcCtD
Duloxetine—Anxiety—Doxorubicin—pancreatic cancer	7.72e-05	0.000312	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	7.7e-05	0.000311	CcSEcCtD
Duloxetine—Discomfort—Doxorubicin—pancreatic cancer	7.66e-05	0.000309	CcSEcCtD
Duloxetine—Anorexia—Epirubicin—pancreatic cancer	7.66e-05	0.000309	CcSEcCtD
Duloxetine—Dry mouth—Doxorubicin—pancreatic cancer	7.58e-05	0.000306	CcSEcCtD
Duloxetine—Vomiting—Docetaxel—pancreatic cancer	7.57e-05	0.000306	CcSEcCtD
Duloxetine—Rash—Docetaxel—pancreatic cancer	7.51e-05	0.000303	CcSEcCtD
Duloxetine—Dermatitis—Docetaxel—pancreatic cancer	7.5e-05	0.000303	CcSEcCtD
Duloxetine—Confusional state—Doxorubicin—pancreatic cancer	7.49e-05	0.000302	CcSEcCtD
Duloxetine—Headache—Docetaxel—pancreatic cancer	7.46e-05	0.000301	CcSEcCtD
Duloxetine—Oedema—Doxorubicin—pancreatic cancer	7.43e-05	0.0003	CcSEcCtD
Duloxetine—Anaphylactic shock—Doxorubicin—pancreatic cancer	7.43e-05	0.0003	CcSEcCtD
Duloxetine—Infection—Doxorubicin—pancreatic cancer	7.38e-05	0.000298	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	7.32e-05	0.000295	CcSEcCtD
Duloxetine—Shock—Doxorubicin—pancreatic cancer	7.31e-05	0.000295	CcSEcCtD
Duloxetine—Nervous system disorder—Doxorubicin—pancreatic cancer	7.29e-05	0.000294	CcSEcCtD
Duloxetine—Thrombocytopenia—Doxorubicin—pancreatic cancer	7.28e-05	0.000294	CcSEcCtD
Duloxetine—Insomnia—Epirubicin—pancreatic cancer	7.26e-05	0.000293	CcSEcCtD
Duloxetine—Tachycardia—Doxorubicin—pancreatic cancer	7.25e-05	0.000293	CcSEcCtD
Duloxetine—Skin disorder—Doxorubicin—pancreatic cancer	7.22e-05	0.000291	CcSEcCtD
Duloxetine—Paraesthesia—Epirubicin—pancreatic cancer	7.21e-05	0.000291	CcSEcCtD
Duloxetine—Hyperhidrosis—Doxorubicin—pancreatic cancer	7.18e-05	0.00029	CcSEcCtD
Duloxetine—Somnolence—Epirubicin—pancreatic cancer	7.14e-05	0.000288	CcSEcCtD
Duloxetine—Anorexia—Doxorubicin—pancreatic cancer	7.08e-05	0.000286	CcSEcCtD
Duloxetine—Nausea—Docetaxel—pancreatic cancer	7.07e-05	0.000285	CcSEcCtD
Duloxetine—Dyspepsia—Epirubicin—pancreatic cancer	7.07e-05	0.000285	CcSEcCtD
Duloxetine—Decreased appetite—Epirubicin—pancreatic cancer	6.98e-05	0.000282	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	6.93e-05	0.00028	CcSEcCtD
Duloxetine—Fatigue—Epirubicin—pancreatic cancer	6.92e-05	0.000279	CcSEcCtD
Duloxetine—Constipation—Epirubicin—pancreatic cancer	6.87e-05	0.000277	CcSEcCtD
Duloxetine—Pain—Epirubicin—pancreatic cancer	6.87e-05	0.000277	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	6.77e-05	0.000273	CcSEcCtD
Duloxetine—Insomnia—Doxorubicin—pancreatic cancer	6.72e-05	0.000271	CcSEcCtD
Duloxetine—Paraesthesia—Doxorubicin—pancreatic cancer	6.67e-05	0.000269	CcSEcCtD
Duloxetine—Feeling abnormal—Epirubicin—pancreatic cancer	6.62e-05	0.000267	CcSEcCtD
Duloxetine—Somnolence—Doxorubicin—pancreatic cancer	6.61e-05	0.000267	CcSEcCtD
Duloxetine—Gastrointestinal pain—Epirubicin—pancreatic cancer	6.57e-05	0.000265	CcSEcCtD
Duloxetine—Dyspepsia—Doxorubicin—pancreatic cancer	6.54e-05	0.000264	CcSEcCtD
Duloxetine—Decreased appetite—Doxorubicin—pancreatic cancer	6.46e-05	0.000261	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	6.42e-05	0.000259	CcSEcCtD
Duloxetine—Fatigue—Doxorubicin—pancreatic cancer	6.41e-05	0.000259	CcSEcCtD
Duloxetine—Urticaria—Epirubicin—pancreatic cancer	6.38e-05	0.000257	CcSEcCtD
Duloxetine—Constipation—Doxorubicin—pancreatic cancer	6.35e-05	0.000256	CcSEcCtD
Duloxetine—Pain—Doxorubicin—pancreatic cancer	6.35e-05	0.000256	CcSEcCtD
Duloxetine—Body temperature increased—Epirubicin—pancreatic cancer	6.35e-05	0.000256	CcSEcCtD
Duloxetine—Abdominal pain—Epirubicin—pancreatic cancer	6.35e-05	0.000256	CcSEcCtD
Duloxetine—Feeling abnormal—Doxorubicin—pancreatic cancer	6.12e-05	0.000247	CcSEcCtD
Duloxetine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	6.08e-05	0.000245	CcSEcCtD
Duloxetine—Hypersensitivity—Epirubicin—pancreatic cancer	5.92e-05	0.000239	CcSEcCtD
Duloxetine—Urticaria—Doxorubicin—pancreatic cancer	5.9e-05	0.000238	CcSEcCtD
Duloxetine—Abdominal pain—Doxorubicin—pancreatic cancer	5.87e-05	0.000237	CcSEcCtD
Duloxetine—Body temperature increased—Doxorubicin—pancreatic cancer	5.87e-05	0.000237	CcSEcCtD
Duloxetine—Asthenia—Epirubicin—pancreatic cancer	5.76e-05	0.000233	CcSEcCtD
Duloxetine—Pruritus—Epirubicin—pancreatic cancer	5.68e-05	0.000229	CcSEcCtD
Duloxetine—Diarrhoea—Epirubicin—pancreatic cancer	5.5e-05	0.000222	CcSEcCtD
Duloxetine—Hypersensitivity—Doxorubicin—pancreatic cancer	5.47e-05	0.000221	CcSEcCtD
Duloxetine—Asthenia—Doxorubicin—pancreatic cancer	5.33e-05	0.000215	CcSEcCtD
Duloxetine—Dizziness—Epirubicin—pancreatic cancer	5.31e-05	0.000214	CcSEcCtD
Duloxetine—Pruritus—Doxorubicin—pancreatic cancer	5.26e-05	0.000212	CcSEcCtD
Duloxetine—Vomiting—Epirubicin—pancreatic cancer	5.11e-05	0.000206	CcSEcCtD
Duloxetine—Diarrhoea—Doxorubicin—pancreatic cancer	5.08e-05	0.000205	CcSEcCtD
Duloxetine—Rash—Epirubicin—pancreatic cancer	5.06e-05	0.000204	CcSEcCtD
Duloxetine—Dermatitis—Epirubicin—pancreatic cancer	5.06e-05	0.000204	CcSEcCtD
Duloxetine—Headache—Epirubicin—pancreatic cancer	5.03e-05	0.000203	CcSEcCtD
Duloxetine—Dizziness—Doxorubicin—pancreatic cancer	4.91e-05	0.000198	CcSEcCtD
Duloxetine—Nausea—Epirubicin—pancreatic cancer	4.77e-05	0.000193	CcSEcCtD
Duloxetine—Vomiting—Doxorubicin—pancreatic cancer	4.72e-05	0.000191	CcSEcCtD
Duloxetine—Rash—Doxorubicin—pancreatic cancer	4.69e-05	0.000189	CcSEcCtD
Duloxetine—Dermatitis—Doxorubicin—pancreatic cancer	4.68e-05	0.000189	CcSEcCtD
Duloxetine—Headache—Doxorubicin—pancreatic cancer	4.66e-05	0.000188	CcSEcCtD
Duloxetine—Nausea—Doxorubicin—pancreatic cancer	4.41e-05	0.000178	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—MMP9—pancreatic cancer	2.9e-05	0.000248	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HEY2—pancreatic cancer	2.9e-05	0.000248	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PRSS1—pancreatic cancer	2.9e-05	0.000248	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTEN—pancreatic cancer	2.88e-05	0.000247	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CNR2—pancreatic cancer	2.87e-05	0.000246	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GLP1R—pancreatic cancer	2.87e-05	0.000246	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CXCL8—pancreatic cancer	2.87e-05	0.000246	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GAST—pancreatic cancer	2.83e-05	0.000242	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCKAR—pancreatic cancer	2.83e-05	0.000242	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AKT1—pancreatic cancer	2.81e-05	0.000241	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	2.8e-05	0.00024	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CNR1—pancreatic cancer	2.8e-05	0.00024	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AGTR1—pancreatic cancer	2.79e-05	0.000239	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JAG2—pancreatic cancer	2.74e-05	0.000235	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CG—pancreatic cancer	2.72e-05	0.000233	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GCG—pancreatic cancer	2.7e-05	0.000231	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MEN1—pancreatic cancer	2.7e-05	0.000231	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SCT—pancreatic cancer	2.68e-05	0.00023	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HEY1—pancreatic cancer	2.68e-05	0.00023	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SRC—pancreatic cancer	2.67e-05	0.000229	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—HRAS—pancreatic cancer	2.67e-05	0.000228	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CD—pancreatic cancer	2.63e-05	0.000225	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VEGFA—pancreatic cancer	2.6e-05	0.000223	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	2.59e-05	0.000222	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AGTR1—pancreatic cancer	2.58e-05	0.000221	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SHH—pancreatic cancer	2.58e-05	0.000221	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—STAT3—pancreatic cancer	2.58e-05	0.000221	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NRAS—pancreatic cancer	2.57e-05	0.00022	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH4—pancreatic cancer	2.56e-05	0.000219	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCK—pancreatic cancer	2.56e-05	0.000219	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IAPP—pancreatic cancer	2.54e-05	0.000218	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STK11—pancreatic cancer	2.54e-05	0.000218	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ARG2—pancreatic cancer	2.51e-05	0.000215	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CNR2—pancreatic cancer	2.49e-05	0.000214	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GLP1R—pancreatic cancer	2.49e-05	0.000214	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCL8—pancreatic cancer	2.49e-05	0.000213	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCKAR—pancreatic cancer	2.45e-05	0.00021	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PRSS1—pancreatic cancer	2.45e-05	0.00021	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTHLH—pancreatic cancer	2.44e-05	0.000209	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTCH1—pancreatic cancer	2.44e-05	0.000209	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MYC—pancreatic cancer	2.39e-05	0.000205	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CD—pancreatic cancer	2.39e-05	0.000204	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TGFB1—pancreatic cancer	2.39e-05	0.000204	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JAG2—pancreatic cancer	2.38e-05	0.000204	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MEN1—pancreatic cancer	2.35e-05	0.000201	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EGFR—pancreatic cancer	2.34e-05	0.0002	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CB—pancreatic cancer	2.29e-05	0.000196	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SHH—pancreatic cancer	2.24e-05	0.000192	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SST—pancreatic cancer	2.23e-05	0.000191	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SMAD4—pancreatic cancer	2.23e-05	0.000191	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH4—pancreatic cancer	2.22e-05	0.00019	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—KRAS—pancreatic cancer	2.21e-05	0.000189	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IAPP—pancreatic cancer	2.21e-05	0.000189	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CG—pancreatic cancer	2.2e-05	0.000189	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL8—pancreatic cancer	2.2e-05	0.000189	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TYMP—pancreatic cancer	2.19e-05	0.000188	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JAG1—pancreatic cancer	2.19e-05	0.000187	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH3—pancreatic cancer	2.18e-05	0.000186	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HES1—pancreatic cancer	2.17e-05	0.000186	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ARG2—pancreatic cancer	2.13e-05	0.000182	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTHLH—pancreatic cancer	2.12e-05	0.000182	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTCH1—pancreatic cancer	2.12e-05	0.000182	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CB—pancreatic cancer	2.08e-05	0.000178	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CNR1—pancreatic cancer	2.06e-05	0.000176	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PIK3CA—pancreatic cancer	2.03e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CG—pancreatic cancer	2e-05	0.000171	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL8—pancreatic cancer	2e-05	0.000171	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GCG—pancreatic cancer	1.99e-05	0.00017	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—pancreatic cancer	1.97e-05	0.000168	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SST—pancreatic cancer	1.94e-05	0.000166	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CD—pancreatic cancer	1.94e-05	0.000166	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CG—pancreatic cancer	1.91e-05	0.000164	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TERT—pancreatic cancer	1.91e-05	0.000163	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGTR1—pancreatic cancer	1.9e-05	0.000163	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JAG1—pancreatic cancer	1.9e-05	0.000162	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH3—pancreatic cancer	1.89e-05	0.000162	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HRAS—pancreatic cancer	1.88e-05	0.000161	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STK11—pancreatic cancer	1.87e-05	0.00016	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TYMP—pancreatic cancer	1.86e-05	0.000159	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HIF1A—pancreatic cancer	1.82e-05	0.000156	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TSC2—pancreatic cancer	1.82e-05	0.000156	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CNR1—pancreatic cancer	1.79e-05	0.000153	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOE—pancreatic cancer	1.78e-05	0.000152	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GLP1R—pancreatic cancer	1.77e-05	0.000151	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CD—pancreatic cancer	1.76e-05	0.000151	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KDR—pancreatic cancer	1.74e-05	0.000149	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—DPYD—pancreatic cancer	1.74e-05	0.000149	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CG—pancreatic cancer	1.74e-05	0.000149	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GCG—pancreatic cancer	1.73e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.69e-05	0.000145	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CD—pancreatic cancer	1.68e-05	0.000144	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT1—pancreatic cancer	1.66e-05	0.000142	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NFKBIA—pancreatic cancer	1.66e-05	0.000142	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	1.65e-05	0.000141	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGTR1—pancreatic cancer	1.65e-05	0.000141	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOTCH1—pancreatic cancer	1.64e-05	0.00014	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SMAD4—pancreatic cancer	1.64e-05	0.00014	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STK11—pancreatic cancer	1.63e-05	0.000139	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL8—pancreatic cancer	1.62e-05	0.000139	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CG—pancreatic cancer	1.61e-05	0.000137	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—NRAS—pancreatic cancer	1.61e-05	0.000137	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HES1—pancreatic cancer	1.6e-05	0.000137	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGF—pancreatic cancer	1.59e-05	0.000136	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.53e-05	0.000131	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CB—pancreatic cancer	1.53e-05	0.000131	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CD—pancreatic cancer	1.53e-05	0.000131	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GLP1R—pancreatic cancer	1.5e-05	0.000128	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—DPYD—pancreatic cancer	1.47e-05	0.000126	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—pancreatic cancer	1.47e-05	0.000126	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.47e-05	0.000125	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—pancreatic cancer	1.46e-05	0.000125	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SMAD4—pancreatic cancer	1.42e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CD—pancreatic cancer	1.41e-05	0.000121	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—pancreatic cancer	1.41e-05	0.000121	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TERT—pancreatic cancer	1.4e-05	0.00012	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	1.4e-05	0.00012	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.4e-05	0.00012	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HES1—pancreatic cancer	1.39e-05	0.000119	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.38e-05	0.000118	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KRAS—pancreatic cancer	1.38e-05	0.000118	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HIF1A—pancreatic cancer	1.34e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TSC2—pancreatic cancer	1.34e-05	0.000115	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.34e-05	0.000114	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CB—pancreatic cancer	1.33e-05	0.000114	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOE—pancreatic cancer	1.31e-05	0.000112	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KDR—pancreatic cancer	1.28e-05	0.00011	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—pancreatic cancer	1.28e-05	0.00011	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CD44—pancreatic cancer	1.28e-05	0.000109	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—pancreatic cancer	1.27e-05	0.000109	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CB—pancreatic cancer	1.23e-05	0.000105	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GCG—pancreatic cancer	1.23e-05	0.000105	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NFKBIA—pancreatic cancer	1.22e-05	0.000104	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TERT—pancreatic cancer	1.22e-05	0.000104	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.22e-05	0.000104	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH1—pancreatic cancer	1.21e-05	0.000103	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CG—pancreatic cancer	1.18e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—NRAS—pancreatic cancer	1.18e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—pancreatic cancer	1.18e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRAS—pancreatic cancer	1.17e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGF—pancreatic cancer	1.17e-05	0.0001	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HIF1A—pancreatic cancer	1.17e-05	9.97e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TSC2—pancreatic cancer	1.16e-05	9.95e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—STK11—pancreatic cancer	1.15e-05	9.87e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—pancreatic cancer	1.14e-05	9.77e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOE—pancreatic cancer	1.14e-05	9.73e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—pancreatic cancer	1.13e-05	9.68e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KDR—pancreatic cancer	1.11e-05	9.54e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—pancreatic cancer	1.1e-05	9.42e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CTNNB1—pancreatic cancer	1.09e-05	9.33e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CD44—pancreatic cancer	1.08e-05	9.27e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—pancreatic cancer	1.08e-05	9.22e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—pancreatic cancer	1.07e-05	9.15e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTEN—pancreatic cancer	1.06e-05	9.1e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.06e-05	9.08e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NFKBIA—pancreatic cancer	1.06e-05	9.07e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.05e-05	9e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH1—pancreatic cancer	1.05e-05	8.98e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CD—pancreatic cancer	1.04e-05	8.89e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GCG—pancreatic cancer	1.04e-05	8.89e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—pancreatic cancer	1.04e-05	8.87e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.03e-05	8.81e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CG—pancreatic cancer	1.03e-05	8.79e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—NRAS—pancreatic cancer	1.03e-05	8.79e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—pancreatic cancer	1.02e-05	8.71e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGF—pancreatic cancer	1.01e-05	8.68e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TYMS—pancreatic cancer	9.91e-06	8.49e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SRC—pancreatic cancer	9.86e-06	8.44e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—STK11—pancreatic cancer	9.76e-06	8.36e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—pancreatic cancer	9.6e-06	8.22e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—pancreatic cancer	9.5e-06	8.14e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NRAS—pancreatic cancer	9.48e-06	8.12e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—pancreatic cancer	9.35e-06	8e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—pancreatic cancer	9.35e-06	8e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	9.17e-06	7.85e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CB—pancreatic cancer	9.06e-06	7.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CD—pancreatic cancer	9.02e-06	7.72e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.94e-06	7.65e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—pancreatic cancer	8.83e-06	7.56e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—pancreatic cancer	8.83e-06	7.56e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—pancreatic cancer	8.81e-06	7.54e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—pancreatic cancer	8.7e-06	7.45e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	8.65e-06	7.4e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—pancreatic cancer	8.64e-06	7.39e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	8.41e-06	7.2e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TYMS—pancreatic cancer	8.4e-06	7.19e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	8.33e-06	7.13e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—pancreatic cancer	8.16e-06	6.98e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	8.12e-06	6.95e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	8.11e-06	6.94e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOE—pancreatic cancer	8.06e-06	6.9e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	8.03e-06	6.87e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	7.87e-06	6.74e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	7.86e-06	6.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	7.83e-06	6.7e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	7.64e-06	6.54e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	7.56e-06	6.47e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	7.51e-06	6.43e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—pancreatic cancer	7.5e-06	6.42e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	7.3e-06	6.25e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	7.28e-06	6.23e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SRC—pancreatic cancer	7.26e-06	6.21e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—pancreatic cancer	7.25e-06	6.21e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	7.23e-06	6.19e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	7.07e-06	6.05e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	7.04e-06	6.03e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—pancreatic cancer	7.02e-06	6.01e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	7e-06	5.99e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	6.98e-06	5.98e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	6.97e-06	5.97e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRAS—pancreatic cancer	6.94e-06	5.94e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	6.84e-06	5.85e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOE—pancreatic cancer	6.83e-06	5.85e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	6.8e-06	5.82e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	6.63e-06	5.68e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—pancreatic cancer	6.5e-06	5.57e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	6.49e-06	5.55e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.47e-06	5.53e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	6.4e-06	5.48e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	6.36e-06	5.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SRC—pancreatic cancer	6.3e-06	5.39e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	6.16e-06	5.28e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	6.14e-06	5.25e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—pancreatic cancer	6.12e-06	5.24e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	6.08e-06	5.2e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	6.06e-06	5.19e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	6.01e-06	5.14e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—pancreatic cancer	5.95e-06	5.09e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—pancreatic cancer	5.65e-06	4.83e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	5.63e-06	4.82e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	5.58e-06	4.77e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—pancreatic cancer	5.53e-06	4.73e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	5.52e-06	4.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	5.52e-06	4.73e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	5.42e-06	4.64e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—pancreatic cancer	5.34e-06	4.57e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	5.22e-06	4.47e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	5.11e-06	4.37e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTEN—pancreatic cancer	4.82e-06	4.12e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	4.79e-06	4.1e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	4.72e-06	4.04e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—pancreatic cancer	4.68e-06	4.01e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—pancreatic cancer	4.64e-06	3.97e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	4.51e-06	3.86e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	4.44e-06	3.8e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTEN—pancreatic cancer	4.08e-06	3.49e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	3.92e-06	3.35e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	3.4e-06	2.91e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	2.88e-06	2.46e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.78e-06	2.38e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—pancreatic cancer	2.35e-06	2.01e-05	CbGpPWpGaD
